MXPA04000317A - Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente. - Google Patents

Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente.

Info

Publication number
MXPA04000317A
MXPA04000317A MXPA04000317A MXPA04000317A MXPA04000317A MX PA04000317 A MXPA04000317 A MX PA04000317A MX PA04000317 A MXPA04000317 A MX PA04000317A MX PA04000317 A MXPA04000317 A MX PA04000317A MX PA04000317 A MXPA04000317 A MX PA04000317A
Authority
MX
Mexico
Prior art keywords
drug
block copolymer
amphiphilic block
complex
positively charged
Prior art date
Application number
MXPA04000317A
Other languages
English (en)
Inventor
Seo Min-Hyo
Original Assignee
Samyang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Corp filed Critical Samyang Corp
Publication of MXPA04000317A publication Critical patent/MXPA04000317A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/664—Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion proporciona un copolimero de bloque amfililico que contiene grupos cationicos el cual es biocompatible y biodegradable, y cuando se usa como un vehiculo de medicamentos para un medicamento anionico, proporciona varias ventajas tales como incremento en la concentracion sanguinea y la estabilidad mejorada del medicamento.
MXPA04000317A 2001-07-14 2002-07-13 Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente. MXPA04000317A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010042563 2001-07-14
PCT/KR2002/001328 WO2003008480A1 (en) 2001-07-14 2002-07-13 Positively charged amphiphilic block copolymer as drug carrier and complex thereof with negatively charged drug

Publications (1)

Publication Number Publication Date
MXPA04000317A true MXPA04000317A (es) 2004-05-04

Family

ID=19712179

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000317A MXPA04000317A (es) 2001-07-14 2002-07-13 Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente.

Country Status (13)

Country Link
US (1) US7226616B2 (es)
EP (1) EP1406946B1 (es)
JP (1) JP4015994B2 (es)
KR (1) KR100527291B1 (es)
CN (1) CN1220717C (es)
AT (1) ATE365183T1 (es)
AU (1) AU2002319922B2 (es)
CA (1) CA2452827C (es)
DE (1) DE60220796T2 (es)
ES (1) ES2287297T3 (es)
MX (1) MXPA04000317A (es)
NZ (1) NZ530588A (es)
WO (1) WO2003008480A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105799A1 (ja) * 2003-05-29 2004-12-09 Toudai Tlo, Ltd. 安定化高分子ミセル
ITMI20031872A1 (it) * 2003-09-30 2005-04-01 Mediolanum Farmaceutici Srl Copolimeri di poliesteri e polivinilpirrolidone.
AU2003272127A1 (en) * 2003-10-24 2005-05-11 Samyang Corporation Polymeric composition for drug delivery
ATE399625T1 (de) * 2004-04-28 2008-07-15 Plasbio Inc Verfahren zum herstellen von abbaubaren polymeren
US7576145B2 (en) 2004-04-28 2009-08-18 Plasbio, Inc. Method for producing degradable polymers
US8007775B2 (en) 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
WO2006095668A1 (ja) * 2005-03-09 2006-09-14 Toray Industries, Inc. 微粒子および医薬品組成物
KR100714458B1 (ko) * 2005-11-24 2007-05-07 헤벨 주식회사 변전설비용 차단기
KR100918524B1 (ko) * 2007-02-14 2009-09-21 성균관대학교산학협력단 온도 및 피에치 민감성 블록공중합체 고분자 하이드로겔을이용한 주사가능한 약물전달체 및 약물전달방법
US8652506B2 (en) * 2008-06-05 2014-02-18 Boston Scientific Scimed, Inc. Bio-degradable block co-polymers for controlled release
WO2010068432A1 (en) 2008-11-25 2010-06-17 Ecole Polytechnique Federale De Lausanne (Epfl) Block copolymers and uses thereof
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
EP2413901A4 (en) * 2009-03-30 2015-05-06 Cerulean Pharma Inc POLYMER CONCRETE CONJUGATES, PARTICLES, COMPOSITIONS AND CORRESPONDING USES
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CN101869712B (zh) * 2009-04-21 2016-01-20 财团法人工业技术研究院 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物
KR101249389B1 (ko) * 2010-10-28 2013-04-03 재단법인대구경북과학기술원 자극반응성 수화젤
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
CN105362251B (zh) * 2015-12-14 2019-02-26 四川大学 DOTAP-mPEG-PLA纳米粒及其纳米粒溶液、载药复合物和制备方法和应用
WO2024009268A1 (en) * 2022-07-07 2024-01-11 Biorchestra Co., Ltd. Micellar nanoparticles and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268705B1 (en) 1986-11-21 1991-01-16 Agfa-Gevaert N.V. Polymeric surfactant
US5035972A (en) 1989-10-31 1991-07-30 E. I. Du Pont De Nemours And Company AB diblock copolymers as charge directors for negative electrostatic liquid developer
US5783178A (en) 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
JP2690276B2 (ja) 1995-01-10 1997-12-10 科学技術振興事業団 静電結合型高分子ミセル薬物担体とその薬剤
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
EP0842209B1 (en) 1995-07-28 2006-10-11 Genzyme Corporation Multiblock biodegradable hydrogels for use as controlled release agents for drugs and tissue treatment agents
BR9610053A (pt) 1995-08-10 1999-07-06 Katoaka Kazunori Polímetro de blocos tendo grupos funcionais sobre ambas extremidades
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
KR20010030891A (ko) * 1997-10-03 2001-04-16 마크로메드 인코퍼레이션 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US5939453A (en) 1998-06-04 1999-08-17 Advanced Polymer Systems, Inc. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
WO2001055360A1 (en) * 2000-01-28 2001-08-02 Infimed Therapeutics, Inc. Slow release protein polymers

Also Published As

Publication number Publication date
CA2452827A1 (en) 2003-01-30
CN1220717C (zh) 2005-09-28
EP1406946B1 (en) 2007-06-20
JP2004536189A (ja) 2004-12-02
AU2002319922B2 (en) 2004-12-16
JP4015994B2 (ja) 2007-11-28
WO2003008480A1 (en) 2003-01-30
US7226616B2 (en) 2007-06-05
DE60220796D1 (de) 2007-08-02
KR20030007176A (ko) 2003-01-23
EP1406946A1 (en) 2004-04-14
NZ530588A (en) 2005-06-24
KR100527291B1 (ko) 2005-11-09
CA2452827C (en) 2009-12-08
CN1531566A (zh) 2004-09-22
DE60220796T2 (de) 2007-10-18
ATE365183T1 (de) 2007-07-15
ES2287297T3 (es) 2007-12-16
US20040234494A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
IL159166A0 (en) Negatively charged amphiphilic block copolymer as drug carrier and complex thereof with positively charged drug
MXPA04000317A (es) Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente.
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2004064618A3 (en) Methods for making oxidation resistant polymeric material
MXPA03010103A (es) Peptidos y composiciones anti-microbianos.
TW200727912A (en) Amphiphilic block copolymers and nano particles comprising the same
IL189629A0 (en) Compositions containing human ctla-4 antibodies
MXPA04001524A (es) 29-enoles de rapamicina.
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
DE60025812D1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
AU8701501A (en) Elastomeric functional biodegradable copolyester amides and copolyester urethanes
MXPA03007140A (es) Derivados de carbolina.
AU2001247968A1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
AU2003279567A1 (en) Sterilizing polymers and preparation and use thereof
YU68702A (sh) Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
AU7918500A (en) Substituted diazepanes
MY134019A (en) Aryl oxime-piperazines useful as ccr5 antagonists
PL357999A1 (en) Lhrh-antagonists, production and use thereof as medicament
WO2003017817A3 (en) Diagnosis, prevention and treatment of cancer
SG142165A1 (en) Biologically active peptides
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
FR2869909B1 (fr) Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status